title: Pancreatic glucose uptake in vivo in men with newly diagnosed type 1 diabetes.
abstract: BACKGROUND
  Due to the restricted accessibility of pancreatic tissue in living man, direct analysis of the events preceding development of autoimmune changes in the pancreas has been problematic. In vivo imaging of insulitis might markedly increase understanding of the events and timing of the events that are necessary for the progression toward overt type 1 diabetes.
  
  
  METHODS
  To evaluate possibilities to visualize insulitis in man in vivo with positron emission tomography, we studied 12 male patients (age 26 +/- 7 yr) with newly diagnosed type 1 diabetes (duration range 0-7 months) and nine age- and sex-matched healthy controls after an overnight fast using 2-[(18)F]fluoro-2-deoxy-D-glucose and [(11)C]methionine. For definition of the regions of interest, pancreas was localized with magnetic resonance imaging or computed tomography-positron emission tomography.
  
  
  RESULTS
  Glucose uptake to the pancreas was markedly higher in the patients with type 1 diabetes than in the healthy controls (22.9 +/- 6.4 vs. 17.8 +/- 6.0 micromol/kg.min, P = 0.039). Glucose uptake to the pancreas of the patients was inversely associated with the duration of diabetes (r = -0.58; P = 0.024), so that in patients with newly diagnosed type 1 diabetes, glucose uptake was higher than in the healthy controls or patients with long duration of diabetes. Methionine uptake to the pancreas of the patients was similar as in the controls (3.7 +/- 1.9 vs. 4.6 +/- 2.4 micromol/kg.min, P = 0.21).
  
  
  CONCLUSIONS
  In patients with type 1 diabetes, glucose uptake to the pancreas is enhanced at or soon after the time of diagnosis.
authors.affiliation: Department of Pediatrics, Central Hospital of Seinäjoki, Hanneksenrinne 7, Seinäjoki, Finland. teemu.kalliokoski@utu.fi
authors.forename: Teemu
authors.initials: T
authors.lastname: Kalliokoski
authors.forename: Pirjo
authors.initials: P
authors.lastname: Nuutila
authors.forename: Kirsi A
authors.initials: KA
authors.lastname: Virtanen
authors.forename: Patricia
authors.initials: P
authors.lastname: Iozzo
authors.forename: Marco
authors.initials: M
authors.lastname: Bucci
authors.forename: Erkki
authors.initials: E
authors.lastname: Svedström
authors.forename: Anne
authors.initials: A
authors.lastname: Roivainen
authors.forename: Kjell
authors.initials: K
authors.lastname: Någren
authors.forename: Tapio
authors.initials: T
authors.lastname: Viljanen
authors.forename: Heikki
authors.initials: H
authors.lastname: Minn
authors.forename: Juhani
authors.initials: J
authors.lastname: Knuuti
authors.forename: Tapani
authors.initials: T
authors.lastname: Rönnemaa
authors.forename: Olli
authors.initials: O
authors.lastname: Simell
mesh_terms: D000328:Adult; D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism*; D019788:Fluorodeoxyglucose F18; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D008297:Male; D018482:Muscle, Skeletal / Q000378:metabolism; D010179:Pancreas / Q000378:metabolism*; D049268:Positron-Emission Tomography
chemical_list: D019788:Fluorodeoxyglucose F18; D005947:Glucose